Novartis launches joint pain gel in India with Phosphagenics' delivery tech

Novartis ($NVS) launched a topical gel in India designed to treat pain associated with osteoarthritis, rheumatism and injury. The gel, called Voveran TPM, uses Novartis' Australian partner Phosphagenics' targeted penetration matrix (TPM) delivery system. The technology uses vitamin E phosphates to, according to Phosphagenics, "enhance dermal, transdermal and oral absorption of compounds." The new formulation is a version of Novartis' Voveran (without TPM), which is currently on the market in India as a 1% diclofenac prescription. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

A self-injection pen prefilled with Brussels-based UCB’s Cimzia (certolizumab pegol) has been made available this week in the U.K. after a positive opinion…

Everstone, a private equity firm specializing in India and Southeast Asia, has finally decided to shell out Rs 220 crore ($33 million) to obtain a 70% stake--a…